Press Release: aap: 23% sales growth in Q2

aap Implantate AG / aap: 23% sales growth in Q2 . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

aap Implantate AG (XETRA: AAQ.DE) generated, according to preliminary figures, sales of EUR 8.0 million in the second quarter of 2014, thereby achieving a result at the upper end of the forecast made at the beginning of the quarter of EUR 7.6 million to EUR 8.2 million. aap generated total sales of EUR 15.2 million in the first half of 2014, of which EUR 14.2 million is attributable to the continued operations (aap Implantate AG excluding EMCM B.V.). As a result of the sale of EMCM B.V. on February 28, the sales figures for the first half-year include sales from EMCM for January and February totaling EUR 1.0 million.

In a year-on-year comparison, the continued operations's quarterly sales grew by 23% over the corresponding sales of EUR 6.6 million in the second quarter of 2013. The key factors in this development were strong quarterly business in the area of biomaterials (biomaterials, bone cements and cementing technology) as well as continued growth in our trauma business. These trends were also decisive for the 12% increase in half-yearly sales to EUR 14.2 million from continued operations. The dynamism of the course of business can been seen clearly here, as the previous year's half-yearly sales figures included EUR 1.6 million in income from project business, which only came to EUR 0.1 million in the first half of 2014.

In EUR million Q2/2014 Q2/2013 Change Sales from continued operations 8.0 6.6 23%

In EUR million H1/2014 H1/2013 Change Sales from continued operations 14.2 12.6 12% Sales from discontinued operations 1.0* 7.0*(2) -86% Sales total 15.2 19.6 -22%

* Sales revenues EMCM B.V. 01-02/2014: EUR 1.2 million less consolidation effects (EUR 0.2 million)

*(2) Sales revenues EMCM B.V. 01-06/2013: EUR 7.4 million less consolidation effects (EUR 0.4 million)

Sales in the trauma area amounted to EUR 3.0 million in the second quarter, of which EUR 1.9 million was attributable to sales of products from the LOQTEQ(R) portfolio. With an increase of LOQTEQ(R) sales of more than 19% on the same quarter in the previous year, the pace of growth was maintained. The trauma area saw growth of 21% to EUR 5.2 million in the first half-year, and here the LOQTEQ(R) system was also a key factor, with growth of 52% to EUR 3.0 million.

In the area of biomaterials, second-quarter sales growth of 50% to EUR 4.9 million, not accounting for project income, continued the good trend for the 2014 financial year. This area reported growth of 42% to EUR 8.5 million in total for the first-half year.

Sales in EUR million Q2/2014 Q2/2013 Change Trauma 3.0 2.8 7% Biomaterials 4.9 3.2 50% Projects 0.1 0.1 0% Other 0 0.5 n.A. Sales from continued operations 8.0 6.6 23%

Sales in EUR million H1/2014 H1/2013 Change Trauma 5.2 4.2 21% Biomaterials 8.5 6.0 42% Projects 0.1 1.6 -91% Other 0.4 0.8 -50% Sales from continued operations 14.2 12.6 12% Sales from discontinued operations 1.0* 7.0*(2) -86% Sales total 15.2 19.6 -22%

* Sales revenues EMCM B.V. 01-02/2014: EUR 1.2 million less consolidation effects (EUR 0.2 million)

*(2) Sales revenues EMCM B.V. 01-06/2013: EUR 7.4 million less consolidation effects (EUR 0.4 million)

Alongside the rapid growth in the trauma business, the following events in the second quarter of 2014 have helped aap to systematically pursue the strategy of creating a focused trauma company:

-- Granting of an additional US patent to extend the LOQTEQ(R) IP family

-- Presentation at the EFORT Congress in London of initial findings from a study as part of market monitoring examining the behavior of LOQTEQ(R) with regard to cold welding: the results show that no case of cold welding has yet been observed in connection with LOQTEQ(R) plates and screws

-- Conclusion of the spin-off of the non-core Dental area by selling the remaining 50% of the shares in aap BM productions GmbH for EUR 1.0 million in cash

-- Conclusion of an agreement with a leading US health care service provider to supply PMMA bone cement in the USA, Canada and Puerto Rico

Publication of the report for the second quarter of 2014 is planned for August 14, 2014.

____________________________________________

About aap Implantate AG

aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: m.heydrich@aap.de

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: aap Implantate AG via Globenewswire

HUG#1814531

--- End of Message ---

aap Implantate AG

Lorenzweg 5 Berlin Germany

WKN: 506660;ISIN: DE0005066609;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Berlin,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;

http://www.aap.de (END) Dow Jones Newswires

   July 04, 2014 09:10 ET (13:10 GMT)- - 09 10 AM EDT 07-04-14